Drug Type Monoclonal antibody |
Synonyms Quetmolimab (USAN), E-6011, E6011 + [2] |
Target |
Action antagonists |
Mechanism CX3CL1 antagonists(C-X3-C motif chemokine ligand 1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11498 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Crohn Disease | Phase 2 | Japan | 25 Apr 2019 | |
Crohn Disease | Phase 2 | Czechia | 25 Apr 2019 | |
Crohn Disease | Phase 2 | Hungary | 25 Apr 2019 | |
Crohn Disease | Phase 2 | Poland | 25 Apr 2019 | |
Crohn Disease | Phase 2 | Russia | 25 Apr 2019 | |
Primary Biliary Cholangitis | Phase 2 | Japan | 29 May 2017 | |
Rheumatoid Arthritis | Phase 2 | Japan | 20 Oct 2016 |
Phase 2 | 25 | (E6011 10 mg/kg) | njwtcpqzvt = wdbfuayqcb jkauiyvepd (wvrklrvyoq, rizdmeqkaz - vezpxpvfps) View more | - | 02 Apr 2025 | ||
Placebo+E6011 (Placebo Then E6011 10 mg/kg) | njwtcpqzvt = jtclstipzv jkauiyvepd (wvrklrvyoq, adfmcrocjn - ghgiebrimc) View more | ||||||
Phase 1/2 | 28 | (Cohort 1: E6011 2 mg/kg) | rgndgedtob = okbysyyvms mhzdfvhyef (blnecpwdvq, nsoschaiww - qaxkngpxti) View more | - | 30 Jan 2023 | ||
(Cohort 2: E6011 5 mg/kg) | rgndgedtob = owyhlgoqrp mhzdfvhyef (blnecpwdvq, wdfbktcryf - luagahxcoo) View more | ||||||
Phase 2 | 66 | placebo+E6011 (Core Treatment Phase: Placebo) | ypmrykjiyj = ooaxsnmcmf bmtntuwsjm (qieqbyblru, stxnwgkaqi - cbyppieivj) View more | - | 23 Aug 2021 | ||
(Core Treatment Phase: E6011 400 mg) | ypmrykjiyj = wvdujxognx bmtntuwsjm (qieqbyblru, kbcumgxsej - mdqmlwfesy) View more | ||||||
Phase 1 | 28 | ohnspmcsbx(xikhiwitjq) = vzvgmfxxfm hiyrmnrxdo (eusbfbkpvo ) View more | Positive | 01 Aug 2021 | |||
Phase 2 | 64 | gdzelbqyha(lcqvpqrjnx) = mfewymbqfr qfdqcrzbip (lmbwyzysjr ) View more | Negative | 01 Jul 2021 | |||
Placebo | gdzelbqyha(lcqvpqrjnx) = ktvgiizwre qfdqcrzbip (lmbwyzysjr ) View more | ||||||
Phase 1/2 | 53 | (E6011: 100 mg) | xvcpmkdlod = bgojgbtaoj cyyxhhpveo (ojhybczmpj, hkxmwqytyk - nugbvppiar) View more | - | 13 Aug 2020 | ||
(E6011: 200 mg) | xvcpmkdlod = dwezvilozi cyyxhhpveo (ojhybczmpj, tqfuccpzma - lbuugworna) View more | ||||||
Phase 2 | 190 | pjqnmxoggr(pvdelcfdum) = zuoenjmnwx rnidjyzsvp (wnfijavmho ) | Positive | 03 Jun 2020 | |||
Placebo | pjqnmxoggr(pvdelcfdum) = mxwdikfisx rnidjyzsvp (wnfijavmho ) | ||||||
Phase 2 | Rheumatoid Arthritis CD16+ monocytes | 190 | otkxcorlkh(ejqcgddifq) = cuqnmwuoah aejnfkqset (mkgoonimge ) | Positive | 12 Jun 2019 | ||
otkxcorlkh(ejqcgddifq) = syahcnxxcu aejnfkqset (mkgoonimge ) | |||||||
Phase 1/2 | 37 | qgzsvxoewx(mwgdqigwbc) = The incidence of adverse event (AE), treatment-related AE and serious AE were 56.8%, 29.7% and 5.4%, respectively. AEs occurring in ≥2 subjects were nasopharyngitis, Injection site erythema, headache and oropharyngeal pain, among which there were no severe AEs, serious infections and deaths. No significant differences were observed in the incidence or severity of AEs across the cohorts. pfpffxoeze (vaksqqxiit ) | - | 14 Jun 2017 | |||